autologous adult induced pluripotent stem cell therapy (Allele Biotechnology & Pharmaceuticals/SCM Lifescience)

N/A

Report date: 2025/03/14 16:46:02

Base Information

Drug Nameautologous adult induced pluripotent stem cell therapy (Allele Biotechnology & Pharmaceuticals/SCM Lifescience)
Drug Alias Nameinduced pluripotent stem cell therapy (Allele Biotechnology & Pharmaceuticals)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Pancreatic stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAllele Biotechnology and Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesScm Lifescience Co LtdAllele Biotechnology and Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A